A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Glioblastoma Clinical Trial

Official title:

A Randomized, Double-blind, Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05753007
• Other study ID #: 23-38341
• Status: Recruiting
• Phase: Phase 2
• Start date: February 15, 2024
• Est. completion date: September 2025

Study information

• Verified date: March 2024
• Source: Mclean Hospital
• Contact: Eduardo Rodriguez Almaraz, MD
• Phone: 415-353-2966
• Email: eduardo.rodriguez[@]ucsf.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain, and sleep disturbance, all of which significantly impact their quality of life. Previous studies have demonstrated the potential of cannabinoids, particularly cannabidiol (CBD), to improve the aforementioned symptoms without conferring significant risks or side effects. Further, recent in-vitro and in-vivo work suggests potential cytotoxic and anti-tumor effects of CBD and other cannabinoids.

This study includes a double-blind, placebo-controlled, 8-week randomized clinical trial assessing the impact of a custom formulated, full-spectrum, hemp-derived ultra-high CBD product on measures of anxiety, pain, and quality of life in newly-diagnosed GBM patients undergoing standard of care (SOC) treatment; the impact of this product vs. placebo on tumor progression will also be assessed. The proposed clinical trial will provide important information that does not currently exist regarding the potential efficacy of a novel full-spectrum, ultra-high CBD product to address clinical symptoms in patients with GBM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: September 2025
• Est. primary completion date: September 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documentation of newly diagnosed glioblastoma, evidenced by neuropathology report and based on World Health Organization (WHO) 2021 classification, and who are to undergo SOC (~ 6 weeks of treatment) with radiation and temozolomide (patients using Optune may be included).

• Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

• Fluent in English.

• Endorses at least moderate levels of anxiety (on the BAI or OASIS) at the screening visit

• Stable medication/psychotherapy regimens for at least 1 month prior to starting the study (excluding new glioblastoma treatment-related medications or radiation).

• Karnofsky Performance Scale (KPS) of 60 or higher.

Exclusion Criteria:

• Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.

• Presence of a condition or abnormality that in the opinion of the Investigators would compromise the safety of the patient or the quality of the data.

• Current substance use disorder, psychotic disorder, bipolar disorder, or eating disorder.

• Current use of recreational cannabis, medical cannabis, or hemp-derived cannabinoid products more frequently than 1x/month; positive urine delta-9 tetrahydrocannabinol (THC) test.

• Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease.

• Current use of valproate (due to potential for drug-drug interactions).

• Currently enrolled in other research studies or clinical trials involving therapeutic interventions.

• Subjects with serum transaminase (ALT, AST, and total bilirubin) levels >3 times upper limit of normal (UNL) <24 hours prior to day 1 of treatment.

• Contraindication to MRI such as non-MR conditional medical devices or ferrous retained foreign bodies.

Related Conditions & MeSH terms

• Glioblastoma

Intervention

Drug:
• Cannabidiol (CBD)
Custom-formulated full-spectrum solution high in cannabidiol
• Placebo
Placebo solution

Locations

Country	Name	City	State
United States	University of California San Francisco Brain Tumor Center	San Francisco	California

Sponsors (3)

Lead Sponsor	Collaborator
Mclean Hospital	Center for Medicinal Cannabis Research, University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI)	The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3 (higher scores indicating more anxiety).	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Primary	Change from Baseline in Anxiety Assessed by the Overall Anxiety Severity and Impairment Scale (OASIS)	The OASIS is a brief 5-item measure used to evaluate the functional impairment cause by anxiety; the frequency and intensity of anxiety, as well as the degree of avoidance and interference with work and social function are rated on a scale of 0 to 4 (higher scores indicating more anxiety).	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Pain Assessed by the Brief Pain Inventory (BPI)	The BPI contains 9 questions that assess the severity of pain, how much relief is provided by treatment, and the functional impact of the pain within the last 24 hours. Lower scores are better.	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Pain Assessed by a Visual Analog Scale (VAS)	The VAS is a 100mm line where patients draw a vertical line to indicate their pain level from 0-100. Lower scores are better.	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Pain Assessed by the Pain Distress Scale (PDS)	The PDS is an 11-point scale one where patients rate their pain by level of distress the pain causes on a scale of 0 to 10. Lower scores are better.	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Pain Assessed by the Pain Disability Index (PDI)	On the PDI, the patient rates how their pain affects 7 different areas of their life on a scale of the level of disability that their pain causes, from "no disability" to "worst disability". Lower scores are better.	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Sleep Quality Assessed by the Pittsburgh Sleep Quality Index (PSQI)	The PSQI contains 19 self-rated questions that assess sleep quality and disturbance over the previous 1-month period. The 19 items yield seven component scores such as sleep latency, sleep duration, and daytime dysfunction, which are then summed to generate a global score (higher scores indicating decreased sleep quality).	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30	The EORTC QLQ-C30 contains 30 questions assessing a cancer patient's quality of life. Lower scores indicate better quality of life and fewer symptoms.	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Change from Baseline in Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BN20	The EORTC QLQ-BN20 module contains 20 additional questions specifically for brain tumor patients. Lower scores indicate better quality of life and fewer symptoms.	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks
Secondary	Patient's Global Impression of Change (PGIC) at Follow-Up	The PGIC is a single-question, 7-point scale depicting a patient's rating of overall improvement from "very much worse" to "very much improved".	1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks